IGDRP Active Substance Review Guide Could Help Regulators – And Applicants
Executive Summary
A group of regulatory authorities has published guidance for harmonizing members' reviews of active substances in drug applications so that it could be adapted for regulatory convergence worldwide – and so that generic drug firms could use it to anticipate regulatory expectations.
You may also be interested in...
'Truly Unique' Four-Agency Work-Sharing Pilot Aims To Cut Regulatory Burden & Speed Decisions
In response to an increasing regulatory workload and the greater complexity of new drugs coming through the pipeline, regulators from Australia, Canada, Singapore and Switzerland are inviting companies to take part in a work-sharing pilot for the assessment of applications for medicines containing a new chemical entity.
'Truly Unique' Four-Agency Work-Sharing Pilot Aims To Cut Regulatory Burden & Speed Decisions
In response to an increasing regulatory workload and the greater complexity of new drugs coming through the pipeline, regulators from Australia, Canada, Singapore and Switzerland are inviting companies to take part in a work-sharing pilot for the assessment of applications for medicines containing a new chemical entity.
Two Regulators-Only Groups Agree To Maximize Synergies Under Single Entity
Two groups comprising regulators from around the world – the International Pharmaceutical Regulators Forum and the International Generic Drug Regulators Programme – are to join forces and form a single entity next year.